ABIVAX: Update on Share Capital and Voting Rights

On February 26, 2026, ABIVAX, listed on Euronext Paris, published an update regarding its share capital. The company announced that, as of January 31, 2026, its share capital consisted of 78,556,680 shares. Furthermore, the total number of theoretical and exercisable voting rights was 80,910,584.

This information complies with the requirements of Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority (AMF). It specifies that theoretical voting rights include shares without voting rights, in accordance with Article 223-11 of the AMF General Regulation.

Based in Paris, ABIVAX is active in the development of therapeutic treatments. Their efforts notably include obefazimod, currently in phase 3 trials for the treatment of ulcerative colitis.